Having listened to this mornings webinar ( I did have internet unlike many !) I think there are some positives there, but the overarching capital markets situation is a major headache.
Other than PTX100 news in December, Cellpryme is probably most likely to deliver the next major news if one of the parties testing it just now wants to do a deal.
Other than that, it is going to be a case of sitting it out.
One thing SYC did say though is that the PTX100 study is a safety study, and so to see results at this early stage is actually quite remarkable. As an IMU shareholder, it is a safety study that's produced results that set its share price alight this week, so PTX is in a very similar position. Wish I had some spare cash because I think the bargain basement prices here right now could reap some serious returns 24 months out
Add to My Watchlist
What is My Watchlist?
